The Experts below are selected from a list of 188340 Experts worldwide ranked by ideXlab platform

Hugh S Markus - One of the best experts on this subject based on the ideXlab platform.

  • magnetic resonance imaging in cerebral small vessel Disease and its use as a surrogate Disease Marker
    International Journal of Stroke, 2011
    Co-Authors: Bhavini Patel, Hugh S Markus
    Abstract:

    Cerebral small vessel Disease is an important cause of vascular cognitive impairment and dementia. On brain imaging, discrete lacunar infarcts and/or more diffuse regions of white matter hyperintensities or leucoaraiosis are seen. Magnetic resonance imaging plays a crucial role in diagnosis, and advanced magnetic resonance imaging techniques are providing new information on Disease mechanisms and offering potential as surrogate Disease Markers. Longitudinal studies have demonstrated detectable progression of lesion load over short time periods, and weak correlations with cognition. Stronger correlations with cognition have been found with diffusion tensor imaging, which is more sensitive to white matter tract structure, supporting a role for disconnection in the pathogenesis of cognitive impairment. Brain volume also consistently correlates with cognition in asymptomatic small vessel Disease, sporadic small vessel Disease, and Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoenc...

  • Magnetic Resonance Imaging in Cerebral Small Vessel Disease and its Use as a Surrogate Disease Marker
    International journal of stroke : official journal of the International Stroke Society, 2011
    Co-Authors: Bhavini Patel, Hugh S Markus
    Abstract:

    Cerebral small vessel Disease is an important cause of vascular cognitive impairment and dementia. On brain imaging, discrete lacunar infarcts and/or more diffuse regions of white matter hyperintensities or leucoaraiosis are seen. Magnetic resonance imaging plays a crucial role in diagnosis, and advanced magnetic resonance imaging techniques are providing new information on Disease mechanisms and offering potential as surrogate Disease Markers. Longitudinal studies have demonstrated detectable progression of lesion load over short time periods, and weak correlations with cognition. Stronger correlations with cognition have been found with diffusion tensor imaging, which is more sensitive to white matter tract structure, supporting a role for disconnection in the pathogenesis of cognitive impairment. Brain volume also consistently correlates with cognition in asymptomatic small vessel Disease, sporadic small vessel Disease, and Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy. Gradient echo magnetic resonance imaging identifies microbleeds in a significant proportion of patients with small vessel Disease, although their role in clinical management remains to be determined. Surrogate Markers to monitor Disease progression and evaluate new therapies would have major clinical use. The greater sensitivity of diffusion tensor imaging parameters and brain volume to change, and the stronger correlation of these parameters with cognition, suggest that they may be more powerful surrogates. However, data from longitudinal and intervention studies are required to determine if this is indeed the case. In this systematic review, we describe the use of both conventional and advanced magnetic resonance imaging techniques in patient groups with the full spectrum of clinical small vessel Disease, from normal populations with WMH to patients groups with lacunar stroke and dementia.

Bhavini Patel - One of the best experts on this subject based on the ideXlab platform.

  • magnetic resonance imaging in cerebral small vessel Disease and its use as a surrogate Disease Marker
    International Journal of Stroke, 2011
    Co-Authors: Bhavini Patel, Hugh S Markus
    Abstract:

    Cerebral small vessel Disease is an important cause of vascular cognitive impairment and dementia. On brain imaging, discrete lacunar infarcts and/or more diffuse regions of white matter hyperintensities or leucoaraiosis are seen. Magnetic resonance imaging plays a crucial role in diagnosis, and advanced magnetic resonance imaging techniques are providing new information on Disease mechanisms and offering potential as surrogate Disease Markers. Longitudinal studies have demonstrated detectable progression of lesion load over short time periods, and weak correlations with cognition. Stronger correlations with cognition have been found with diffusion tensor imaging, which is more sensitive to white matter tract structure, supporting a role for disconnection in the pathogenesis of cognitive impairment. Brain volume also consistently correlates with cognition in asymptomatic small vessel Disease, sporadic small vessel Disease, and Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoenc...

  • Magnetic Resonance Imaging in Cerebral Small Vessel Disease and its Use as a Surrogate Disease Marker
    International journal of stroke : official journal of the International Stroke Society, 2011
    Co-Authors: Bhavini Patel, Hugh S Markus
    Abstract:

    Cerebral small vessel Disease is an important cause of vascular cognitive impairment and dementia. On brain imaging, discrete lacunar infarcts and/or more diffuse regions of white matter hyperintensities or leucoaraiosis are seen. Magnetic resonance imaging plays a crucial role in diagnosis, and advanced magnetic resonance imaging techniques are providing new information on Disease mechanisms and offering potential as surrogate Disease Markers. Longitudinal studies have demonstrated detectable progression of lesion load over short time periods, and weak correlations with cognition. Stronger correlations with cognition have been found with diffusion tensor imaging, which is more sensitive to white matter tract structure, supporting a role for disconnection in the pathogenesis of cognitive impairment. Brain volume also consistently correlates with cognition in asymptomatic small vessel Disease, sporadic small vessel Disease, and Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy. Gradient echo magnetic resonance imaging identifies microbleeds in a significant proportion of patients with small vessel Disease, although their role in clinical management remains to be determined. Surrogate Markers to monitor Disease progression and evaluate new therapies would have major clinical use. The greater sensitivity of diffusion tensor imaging parameters and brain volume to change, and the stronger correlation of these parameters with cognition, suggest that they may be more powerful surrogates. However, data from longitudinal and intervention studies are required to determine if this is indeed the case. In this systematic review, we describe the use of both conventional and advanced magnetic resonance imaging techniques in patient groups with the full spectrum of clinical small vessel Disease, from normal populations with WMH to patients groups with lacunar stroke and dementia.

Teresa Tejerina - One of the best experts on this subject based on the ideXlab platform.

  • TGF-beta1: a novel target for cardiovascular pharmacology.
    Cytokine & growth factor reviews, 2007
    Co-Authors: Santiago Redondo, Carlos G Santos-gallego, Teresa Tejerina
    Abstract:

    Transforming growth factor beta-1 (TGF-beta1) plays a key role in cardiovascular Disease by a process which allows the loss of its protective properties. The first therapeutic attempt to restore its function by selectively designed novel drugs are being made. In addition, it has been recognized that the TGF-beta1 pathway is involved in the vascular mechanism of action of some current clinical drugs, such as acetylsalicylic acid, thiazolidinediones and statins. The aim of this paper is to review the possible value of TGF-beta1 as both a Disease Marker and a therapeutical target for cardiovascular Disease.

  • TGF-β1: a novel target for cardiovascular pharmacology
    Cytokine & Growth Factor Reviews, 2007
    Co-Authors: Santiago Redondo, Carlos G Santos-gallego, Teresa Tejerina
    Abstract:

    Abstract Transforming growth factor beta-1 (TGF-β1) plays a key role in cardiovascular Disease by a process which allows the loss of its protective properties. The first therapeutic attempt to restore its function by selectively designed novel drugs are being made. In addition, it has been recognized that the TGF-β1 pathway is involved in the vascular mechanism of action of some current clinical drugs, such as acetylsalicylic acid, thiazolidinediones and statins. The aim of this paper is to review the possible value of TGF-β1 as both a Disease Marker and a therapeutical target for cardiovascular Disease.

Santiago Redondo - One of the best experts on this subject based on the ideXlab platform.

  • TGF-beta1: a novel target for cardiovascular pharmacology.
    Cytokine & growth factor reviews, 2007
    Co-Authors: Santiago Redondo, Carlos G Santos-gallego, Teresa Tejerina
    Abstract:

    Transforming growth factor beta-1 (TGF-beta1) plays a key role in cardiovascular Disease by a process which allows the loss of its protective properties. The first therapeutic attempt to restore its function by selectively designed novel drugs are being made. In addition, it has been recognized that the TGF-beta1 pathway is involved in the vascular mechanism of action of some current clinical drugs, such as acetylsalicylic acid, thiazolidinediones and statins. The aim of this paper is to review the possible value of TGF-beta1 as both a Disease Marker and a therapeutical target for cardiovascular Disease.

  • TGF-β1: a novel target for cardiovascular pharmacology
    Cytokine & Growth Factor Reviews, 2007
    Co-Authors: Santiago Redondo, Carlos G Santos-gallego, Teresa Tejerina
    Abstract:

    Abstract Transforming growth factor beta-1 (TGF-β1) plays a key role in cardiovascular Disease by a process which allows the loss of its protective properties. The first therapeutic attempt to restore its function by selectively designed novel drugs are being made. In addition, it has been recognized that the TGF-β1 pathway is involved in the vascular mechanism of action of some current clinical drugs, such as acetylsalicylic acid, thiazolidinediones and statins. The aim of this paper is to review the possible value of TGF-β1 as both a Disease Marker and a therapeutical target for cardiovascular Disease.

Enzo Emanuele - One of the best experts on this subject based on the ideXlab platform.

  • Soluble receptor for advanced glycation end products: from Disease Marker to potential therapeutic target.
    Current medicinal chemistry, 2006
    Co-Authors: Diego Geroldi, Colomba Falcone, Enzo Emanuele
    Abstract:

    The receptor for advanced glycation end products (RAGE) is a cell-bound receptor of the immunoglobulin superfamily which may be activated by a variety of proinflammatory ligands including advanced glycoxidation end products, S100/calgranulins, high mobility group box 1, and amyloid beta-peptide. RAGE has a secretory splice isoform, soluble RAGE (sRAGE), that lacks the transmembrane domain and therefore circulates in plasma. By competing with cell-surface RAGE for ligand binding, sRAGE may contribute to the removal/neutralization of circulating ligands thus functioning as a decoy. Clinical studies have recently shown that higher plasma levels of sRAGE are associated with a reduced risk of coronary artery Disease, hypertension, the metabolic syndrome, arthritis and Alzheimer's Disease. Increasing the production of plasma sRAGE is therefore considered to be a promising therapeutic target that has the potential to prevent vascular damage and neurodegeneration. This review presents the state of the art in the use of sRAGE as a Disease Marker and discusses the therapeutic potential of targeting sRAGE for the treatment of inflammation-related Diseases such as atherosclerosis, arthritis and Alzheimer's Disease.